This stock is flashing a long-term overbought signal -- and its recent moves concern me.
You should be watching how DexCom is trading.
That may prove difficult, so trail up stops on any long positions.
Unintended consequences of the law could benefit these operators.

Tenet Nearing a Breakout Real Money Pro($)

This possible Obamacare winner also gains favor with the charts.
Its pipeline appears strong enough to overcome patent-expiration issues.
If the stock doesn't breach support, here's where I'd buy in.

Count on Gilead, Watch Celgene Real Money Pro($)

These two biotechs are for adventurous buyers.

Two Attractive Biotech Plays Real Money Pro($)

Speculative growth investors might want to test the water.
Investors may be worried about Sovaldi's price.

Columnist Conversations

Ugly end to a challenging week as stocks post around three percent declines for the opening month of 2015. Oil...
I have scaled further into a TLT short - scaling all the way up to $138.35 this morning. And I have scaled int...
Market slightly down despite the boost Amazon (AMZN) is giving the NASDAQ. Biotech also continues to be a stro...
There are a number of interesting technical signals on the weekly and daily Berkshire Hathaway (BRK/B) charts....


Columnist Tweets


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.